ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter

Drugmaker Takeda to introduce value-based pricing in Europe

Japanese company to refund Crohn's disease patients with no improvements

Biologics, which require complex manufacturing processes, carry hefty price tags.

TOKYO -- Takeda Pharmaceutical will adopt value-based pricing for expensive biopharmaceuticals starting in Europe, becoming the first Japanese drugmaker to test a method that charges only patients whose conditions have improved and possibly igniting a debate for introduction here. 

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more